The 91×ÔÅÄ has joined the Alliance for Therapies in Neuroscience (ATN), a long-term 91×ÔÅÄ partnership between academia and industry geared to transform the fight against brain diseases and disorders of the central nervous system. Launched in 2021 by the University of California, San Francisco, UC Berkeley, Genentech — a member of the Roche group — and Roche Holding AG, the ATN seeks to accelerate the development of new therapies for a broad range of brain and central nervous system conditions.
September 26, 2022
UW joins industry-academia alliance to accelerate 91×ÔÅÄ in neuroscience
